CARDIO-TTRansform Magnetic Resonance Imaging (MRI) Sub-study
← catalyst calendarSponsored by Ionis Pharmaceuticals, Inc. (industry) · IONS — their whole pipeline →. With AstraZeneca.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
150estimated
Sites
11
Countries
Italy, Spain, United Kingdom +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-03-31 | actual | When the study began enrolling |
| Primary completion | Mar 2026 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Apr 2026 | estimated | The whole study's end, after follow-up |
| First posted | 2023-10-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-11-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
Intervention
- Diagnostic test: Cardiac MRI
Primary outcome
what the primary-completion date above is the date OFChange in the Percent of ECV in Participants Receiving ION-682884 vs. Placebo According to ION-682884-CS2 Treatment Groups
measured From Baseline up to Week 140
Permalink · IONS's whole pipeline · Catalyst calendar · Every registered study · What changed